Kevin Hollevoet

Kevin Hollevoet

Kevin Hollevoet

Director of Scientific & Business Development - 2 Bridge

Kevin Hollevoet is a Bio-engineer in Cell and Gene Biotechnology, graduated from Ghent University in 2008. During his PhD at that same university, he oversaw a Belgian multi-center clinical trial that provided lasting insights on the use of biomarkers in the management of malignant mesothelioma. In 2011, he moved to the National Cancer Institute (Bethesda, MD) for a two-year postdoc on antibody-toxin conjugates. His pre-clinical findings in pancreatic cancer contributed to the initiation of clinical trials in that indication.

 

After returning to Belgium in 2013, Kevin built and directed the Antibody Gene Transfer Program at the University of Leuven, focused on building a platform for DNA-based delivery of biologics. In parallel, he matured an associated spinoff project in collaboration with PharmAbs, the KU Leuven Antibody Center, and obtained a Postgraduate degree in Innovation and Entrepreneurship. He continues to advise the Program’s R&D and translational strategy in the capacity of Guest Research Professor. Throughout the years, his scientific and entrepreneurial work has been recognized with multiple awards.

 

In Sept 2018, Kevin joined 2 Bridge, a company passionate about building life sciences companies to benefit patient health. As Director of Scientific and Business development, he has supported various early-stage biotech companies in operational and management roles.

Join us in person on 19 May

Flanders.bio Strategic Partners

Flanders.bio Supporting Partners